Synthesis of new N-containing maltooligosaccharides, α-amylase inhibitors, and their biological activities

Abstract

Fifteen new N-containing maltooligosaccharides were obtained using the chemoenzymatic method. Among these compounds, maltooligosaccharides having 6- amino-6-deoxy-D-sorbitol residue, (3R,4R,5R,6S)-hexahydro-3,4,5,6- tetrahydroxy-1H-azepine residue, and (3R,5R)-3,4,5-trihydroxypiperidine residue at the reducing end showed strong inhibitory activities for human pancreatic α-amylase (HPA) (EC 3.2.1.1) and human salivary amylase (HSA). The administration of (3R,4R,5R,6S)-hexahydro-3,5,6-trihydroxy-1H-azepine-4- yl O-α-D-glucopyranosyl-(1→4)-α-D-glucopyranoside (13, IC50=4.3x10-5M for HPA, IC50=8.2x10-5M for HSA) and (3R,5R)-3,5-dihydroxypiperidine-4- yl O-α-D-glucopyranosyl-(1→4)-α-D-glucopyranoside (18, IC50=3.4x10-5M for HPA, IC50=4.6 x 10-5 M for HSA) to ICR mice suppressed postprandial hyperglycemia.